Study of PTK787 in the Treatment of Patients With Non-Metastatic Androgen Independent Prostate Cancer

Inclusion Criteria: * Histologic or cytologic diagnosis of prostate cancer * No evidence of metastatic disease * PSA-only progression despite androgen depravation therapy and antiandrogen withdrawal * Patients must maintain castrate levels of testosterone (\<50ng/mL) or continue on LHRH ( Luteinizing Hormone-releasing Hormone) analog therapy. * ECOG (Eastern Cooperative Oncology Group) performance status of 0-2 (A measure of quality of life where 0 represents asymptomatic and 5 represents death) * No prior anti-VEGF therapy is allowed * No investigational or commercial agents or therapies other than LHRH agonists/antagonists may be administered concurrently with intent to treat the patient's malignancy * Age greater than or equal to 18 years * Life expectancy greater than 6 months * Normal organ and marrow function obtained within 14 days prior to registration * Must use adequate contraception prior to study entry and for the duration of study participation. Exclusion Criteria: * Patients may continue on a daily multivitamin, but all other herbal or alternative food supplements must be discontinued before registration. * Patients must be on stable doses of bisphosphonates which have been started no less than 6 weeks prior to protocol therapy. * Uncontrolled incurrent illness * Patients with a "currently active" second malignancy are not eligible. * Major surgery less than or equal to 4 weeks prior to randomization * Prior chemotherapy less than or equal to 3 weeks prior to registration * Prior biologic or immunotherapy less than or equal to 2 weeks prior to registration * Prior investigational drugs of any kind less than or equal to 4 weeks prior to registration * Patients who have had full field radiotherapy less than or equal to 4 weeks or limited field radiotherapy equal or less than 2 weeks prior to registration. * Patients must not be on nonsteroidal antiandrogen blockade. * Patients must have no evidence of disease on bone scan or computed tomography (CT) scan of the abdomen/pelvis.